利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.017 秒)

    Pharmaceutical compositions
    2.
    发明授权
    Pharmaceutical compositions 失效
    药物组合物

    公开(公告)号：US08460702B2

    公开(公告)日：2013-06-11

    申请号：US12097163

    申请日：2006-12-15

    申请人： Alan Smith ,  Ann Margaret Dyer

    发明人： Alan Smith ,  Ann Margaret Dyer

    IPC分类号： A61K9/64 ,  A61K9/14

    CPC分类号： A61K9/2009 ,  A61K9/1611 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/2866 ,  A61K31/195

    摘要： Sustained release pharmaceutical compositions contain a drug; microcrystalline cellulose; a diluent (such as starch); a glidant (such as talc); and one or more of ethylcellulose, stearic acid and a salt of stearic acid. Preferred drugs include those that exhibit a low degree of solubility combined with a high potency, particularly thyroid hormones, such as liothyronine.

    摘要翻译： 缓释药物组合物含有药物; 微晶纤维素; 稀释剂（如淀粉）; 助流剂（如滑石粉）; 和一种或多种乙基纤维素，硬脂酸和硬脂酸盐。 优选的药物包括与高效力结合的低溶解度的药物，特别是甲状腺激素，如氨基罗丹宁。

    Pharmaceutical Compositions
    4.
    发明申请
    Pharmaceutical Compositions 失效
    药物组合物

    公开(公告)号：US20090130202A1

    公开(公告)日：2009-05-21

    申请号：US12097163

    申请日：2006-12-15

    申请人： Alan Smith ,  Ann Margaret Dyer

    发明人： Alan Smith ,  Ann Margaret Dyer

    IPC分类号： A61K9/48 ,  A61K31/195 ,  A61K9/14

    CPC分类号： A61K9/2009 ,  A61K9/1611 ,  A61K9/2054 ,  A61K9/2095 ,  A61K9/2866 ,  A61K31/195

    摘要： Sustained release pharmaceutical compositions contain a drug; microcrystalline cellulose; a diluent (such as starch); a glidant (such as talc); and one or more of ethylcellulose, stearic acid and a salt of stearic acid. Preferred drugs include those that exhibit a low degree of solubility combined with a high potency, particularly thyroid hormones, such as liothyronine.

    摘要翻译： 缓释药物组合物含有药物; 微晶纤维素; 稀释剂（如淀粉）; 助流剂（如滑石粉）; 和一种或多种乙基纤维素，硬脂酸和硬脂酸盐。 优选的药物包括与高效力结合的低溶解度的药物，特别是甲状腺激素，如氨基罗丹宁。

    Liquid pharmaceutical formulation containing zotepine
    5.
    发明授权
    Liquid pharmaceutical formulation containing zotepine 失效
    含有zotepine的液体药物制剂

    公开(公告)号：US06239165B1

    公开(公告)日：2001-05-29

    申请号：US09600980

    申请日：2000-07-25

    申请人： Ann Margaret Dyer ,  Alan Smith

    发明人： Ann Margaret Dyer ,  Alan Smith

    IPC分类号： A61K3138

    CPC分类号： A61K9/0095 ,  A61K47/12 ,  A61K47/26

    摘要： A liquid pharmaceutical formulation comprising a) 2 to 7% w/v of Zotepine; b) 0.5 to 35% w/v of an organic acid selected from the group consisting of ascorbic acid, citric acid, fumaric acid, glutaric acid, lactic acid, malic acid, sorbic acid and tartaric acid; c) 15 to 60% v/v of ethanol and d) a liquid diluent to 100%; which may be used as drops or in a drink.

    摘要翻译： 一种液体药物制剂，其包含a）2-7％（w / v）的Zotepine; b）0.5至35％w / v的选自抗坏血酸，柠檬酸，富马酸，戊二酸，乳酸，苹果酸，山梨酸和酒石酸的有机酸; c）15至60％v / v的乙醇和d）液体稀释剂至100％; 其可以用作滴剂或饮料。

    Compositions for the oral delivery of corticosteroids
    7.
    发明授权
    Compositions for the oral delivery of corticosteroids 有权
    口服皮质类固醇的组合物

    公开(公告)号：US08491932B2

    公开(公告)日：2013-07-23

    申请号：US12992182

    申请日：2009-05-07

    申请人： Peter Watts ,  Ann Margaret Dyer

    发明人： Peter Watts ,  Ann Margaret Dyer

    IPC分类号： A61K9/50 ,  A61K9/22 ,  A61K9/52 ,  A61P29/00 ,  A61P13/12 ,  A61P1/00

    CPC分类号： A61K9/4891 ,  A61K9/5047 ,  A61K9/5078

    摘要： An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained release component is predominately released from the capsule in the intestine following oral administration. A drug delivery composition for delivering a corticosteroid drug to the intestine also includes: (a) a sustained release component comprising a corticosteroid drug, an alkali-containing ethylcellulose material and an acid; and (b) a delayed release component which substantially prevents release of the sustained release component until the composition reaches the intestine following oral administration. The compositions of the invention are useful for treating inflammatory diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis, and for treating glomerulonephritis.

    摘要翻译： 口服药物递送组合物包括持续释放组分，其包含皮质类固醇药物，并且其包含在经过治疗的胶囊中，使得持续释放组分在口服给药后主要从肠中释放出胶囊。 用于将皮质类固醇药物递送至肠道的药物递送组合物还包括：（a）包含皮质类固醇药物，含碱性乙基纤维素材料和酸的缓释组分; 和（b）延迟释放组分，其基本上防止缓释组分的释放，直到口服给药后组合物到达肠。 本发明的组合物可用于治疗胃肠道炎症性疾病，如克罗恩病和溃疡性结肠炎，以及治疗肾小球性肾炎。

    COMPOSITIONS FOR THE ORAL DELIVERY OF CORTICOSTEROIDS
    8.
    发明申请
    COMPOSITIONS FOR THE ORAL DELIVERY OF CORTICOSTEROIDS 有权
    用于口服递送角质层的组合物

    公开(公告)号：US20110104269A1

    公开(公告)日：2011-05-05

    申请号：US12992182

    申请日：2009-05-07

    申请人： Peter Watts ,  Ann Margaret Dyer

    发明人： Peter Watts ,  Ann Margaret Dyer

    IPC分类号： A61K31/58 ,  A61K9/00 ,  A61K9/50 ,  A61K9/22 ,  A61K9/52 ,  A61P29/00 ,  A61P13/12 ,  A61P1/00

    CPC分类号： A61K9/4891 ,  A61K9/5047 ,  A61K9/5078

    摘要： An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained release component is predominately released from the capsule in the intestine following oral administration. A drug delivery composition for delivering a corticosteroid drug to the intestine also includes: (a) a sustained release component comprising a corticosteroid drug, an alkali-containing ethylcellulose material and an acid; and (b) a delayed release component which substantially prevents release of the sustained release component until the composition reaches the intestine following oral administration. The compositions of the invention are useful for treating inflammatory diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis, and for treating glomerulonephritis.

    摘要翻译： 口服药物递送组合物包括持续释放组分，其包含皮质类固醇药物，并且其包含在经过治疗的胶囊中，使得持续释放组分在口服给药后主要从肠中释放出胶囊。 用于将皮质类固醇药物递送至肠道的药物递送组合物还包括：（a）包含皮质类固醇药物，含碱性乙基纤维素材料和酸的缓释组分; 和（b）延迟释放组分，其基本上防止缓释组分的释放，直到口服给药后组合物到达肠。 本发明的组合物可用于治疗胃肠道炎症性疾病，如克罗恩病和溃疡性结肠炎，以及治疗肾小球性肾炎。